Ignite Creation Date:
2025-12-25 @ 2:54 AM
Ignite Modification Date:
2026-03-03 @ 12:42 AM
Study NCT ID:
NCT02764333
Status:
COMPLETED
Last Update Posted:
2021-11-30
First Post:
2016-05-04
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-05-06
Start Date Type:
ACTUAL
Primary Completion Date:
2021-01-20
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-01-20
Completion Date Type:
ACTUAL
First Submit Date:
2016-05-04
First Submit QC Date:
None
Study First Post Date:
2016-05-06
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2021-11-01
Results First Submit QC Date:
None
Results First Post Date:
2021-11-30
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-11-01
Last Update Post Date:
2021-11-30
Last Update Post Date Type:
ACTUAL